Novartis' Sandoz division has filed its biosimilar of Humira in the US, aiming to take a share of its multi-billion dollar revenues once its patent expires. The generics and biosimilars arm of ...

After years of patent protection, biosimilars for Humira are set to enter the US market in 2023. The arrival of these drugs has been widely anticipated throughout the healthcare industry.

Total Net Revenues: Over $13.3 billion, $550 million ahead of expectations. Ex-Humira Platform Sales Growth: More than 21% increase. Immunology Revenues: Over $6.2 billion, exceeding expectations.

Sanofi’s development of an oral spin on Humira’s mechanism has hit a setback. The candidate fell short in a phase 2 psoriasis trial, prompting the French drugmaker to pull back from plans to ...

Soft spots in the report came from the usual suspects—worse-than-expected erosion of Humira and the continued weakness of the aesthetics, eye care, and other segments. But overall, a lot more ...

As noted above, 1 is the most prevalent stylized logo number in the USPTO’s files. After that, though, come 7 and the coveted 8, suggesting a particular visual appeal in the form of these numerals.

U.S. Humira revenue guidance was lowered by $500 million to $3.5 billion due to faster-than-expected erosion from biosimilar competition. Neuroscience is projected to generate $10 billion in 2025 ...

Drake University and Des Moines Area Community College could be close to a settlement agreement in a hotly contested legal battle over the schools' logos and trademarks. New court records show a ...

which are expected to more than compensate for the anticipated decline in Humira sales. For event-driven traders, understanding historical stock performance around earnings announcements can offer ...